However, tumor resistance resulting from clinical used aromataseinhibitors and antiestrogens is unpredictable.
2
Then a newer class of drugs, the aromataseinhibitors, was developed.
3
Now, a new class of agents called aromataseinhibitors have emerged as an alternative.
4
Letrozole is one of aromataseinhibitors frequently used in treatment of men with oligospermia.
5
These concepts provide a strong rationale for studies of aromataseinhibitors to prevent breast cancer.
6
Third generation of aromataseinhibitors appear better than tamoxifen in the adjuvant treatment of postmenopausal women.
7
Approval of LH-RH analogs and aromataseinhibitors has brought a new era in breast cancer treatment.
8
Most postmenopausal women who are diagnosed with breast cancer are prescribed anticancer drugs called aromataseinhibitors.
9
Recent clinical studies suggest that greater responses occur when aromataseinhibitors are used as first line treatment.
10
Different chemoprevention trials are ongoing to compare different selective estrogen receptor modulators and aromataseinhibitors with tamoxifen.
11
Whereas tamoxifen displays partial ER agonistic effects in bone, aromataseinhibitors increase bone resorption and fracture risk.
12
The current findings have implications for current trials evaluating aromataseinhibitors and other chemopreventive agents for this disease.
13
About 10% of postmenopausal women on aromataseinhibitors take bisphosphonates to help keep their bones strong.
14
Tamoxifen was the first drug to block the effects of estrogen and the aromataseinhibitors are the next generation.
15
Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromataseinhibitors or anti-estrogens such as tamoxifen.
16
It looked at aromataseinhibitors, which stop post-menopausal women producing oestrogen, as oestrogen stimulates the growth of certain breast cancer cells.